Doi, Toshihiko <br/><br/>
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors.  [electronic resource] 

 -  Investigational new drugs  06 2019 
 - 507-518 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-018-0697-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--pharmacokinetics<br/>Drug Combinations<br/>Drug Therapy, Combination<br/>Enzyme Inhibitors--pharmacokinetics<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Oxonic Acid--pharmacokinetics<br/>Prognosis<br/>Pyrimidines--pharmacokinetics<br/>Pyrophosphatases--antagonists & inhibitors<br/>Sulfonamides--pharmacokinetics<br/>Tegafur--pharmacokinetics<br/>Tissue Distribution